Tags

Type your tag names separated by a space and hit enter

Chronic hepatitis C virus infection after treatment for pediatric malignancy.
Blood 1997; 90(3):1315-20Blood

Abstract

Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure.

Authors+Show Affiliations

Department of Pediatrics, Università di Padova, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9242567

Citation

Cesaro, S, et al. "Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy." Blood, vol. 90, no. 3, 1997, pp. 1315-20.
Cesaro S, Petris MG, Rossetti F, et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood. 1997;90(3):1315-20.
Cesaro, S., Petris, M. G., Rossetti, F., Cusinato, R., Pipan, C., Guido, M., ... Zanesco, L. (1997). Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood, 90(3), pp. 1315-20.
Cesaro S, et al. Chronic Hepatitis C Virus Infection After Treatment for Pediatric Malignancy. Blood. 1997 Aug 1;90(3):1315-20. PubMed PMID: 9242567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic hepatitis C virus infection after treatment for pediatric malignancy. AU - Cesaro,S, AU - Petris,M G, AU - Rossetti,F, AU - Cusinato,R, AU - Pipan,C, AU - Guido,M, AU - Masiero,L, AU - Botta,G A, AU - Meloni,G A, AU - Zanesco,L, PY - 1997/8/1/pubmed PY - 1997/8/1/medline PY - 1997/8/1/entrez SP - 1315 EP - 20 JF - Blood JO - Blood VL - 90 IS - 3 N2 - Sera of 658 patients who had completed treatment for pediatric malignancy were analyzed by a second-generation enzyme-linked immunosorbent assay and recombinant immunoblot assay test to assess the prevalence of hepatitis C virus (HCV)-seropositivity. All HCV-seropositive patients underwent detailed clinical, laboratory, virologic, and histologic study to analyze the course of HCV infection. One hundred seventeen of the 658 patients (17.8%) were positive for HCV infection markers. Among the 117 anti-HCV+ patients, 41 (35%) were also positive for markers of hepatitis B virus infection with or without delta virus infection markers, 91 (77.8%) had previously received blood product transfusions, and 25 (21.4%) showed a normal alanine aminotransferase (ALT) level during the last 5-year follow-up (11 of them never had abnormal ALT levels). The remaining 92 patients showed ALT levels higher than the upper limit of normal range. Eighty-one of 117 (70%) anti-HCV+ patients were HCV-RNA+, with genotype 1b being present in most patients (54%). In univariate analysis, no risk factor for chronic liver disease was statistically significant. In this study, the prevalence of HCV infection was high in patients who were treated for a childhood malignancy. In about 20% of anti-HCV+ patients, routes other than blood transfusions are to be considered in the epidemiology of HCV infection. After a 14-year median follow-up, chronic liver disease of anti-HCV+ positive patients did not show progression to liver failure. SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/9242567/Chronic_hepatitis_C_virus_infection_after_treatment_for_pediatric_malignancy_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -